STRATA Skin Sciences(US:SSKN) Globenewswire·2025-11-06 13:00Core Insights - STRATA Skin Sciences, Inc. has received confirmation from the Centers for Medicare & Medicaid Services (CMS) regarding continued reimbursement for excimer laser treatments, with an expansion of CPT code descriptors expected in 2027 [1][2][7] Group 1: Reimbursement and Regulatory Updates - CMS has affirmed ongoing reimbursement for excimer laser treatments under CPT codes 96920, 96921, and 96922, ensuring uninterrupted patient access [7] - The Final Rule indicates a payment increase of approximately 3.5% for all three codes in calendar year 2026 compared to 2025 [7] - The current CPT code family remains exclusive to excimer laser technology until at least the 2027 descriptor updates, reinforcing STRATA's position against other technologies being billed under these codes [7] Group 2: Future Indications and Clinical Engagement - CMS recognizes the upcoming expansion of excimer laser procedure eligibility to include additional inflammatory and autoimmune conditions, effective January 1, 2027 [7] - STRATA is actively engaging with commercial insurance providers to ensure that individual coverage policies extend the excimer laser exclusivity beyond 2027 [3][4] - The company plans to incorporate extensive clinical and real-world cost data in the 2027 rulemaking process, which will be reviewed alongside recommendations from the American Medical Association (AMA) [2][4] Group 3: Commitment to Patients and Providers - STRATA's XTRAC excimer laser is FDA-cleared and clinically proven for treating various dermatologic conditions, including psoriasis and vitiligo [6] - The company is committed to partnering with clinicians, patient advocates, and payers to ensure the availability of safe and effective treatment options [6] - STRATA supports over 840 partner clinics and aims to expand the adoption of excimer laser procedures across immune-mediated skin diseases [4]